Abstract
Acalabrutinib is a second-generation, highly selective Bruton's Tyrosine Kinase inhibitor (BTKi) indicated for use in some mature B-cell malignancies.......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
